Abstract
Metformin is an oral anti-hyperglycemic derivative extensively used for the treatment of type II diabetes. Following oral administration, metformin exhibits an incomplete absorption and therefore repeated administrations of high doses of this drug are required for successful therapy due to its short biological half-life. For this, development of novel drug delivery systems for metformin might be useful to decrease the dosing frequency, to enhance its bioavailability, to reduce gastrointestinal adverse effects, and to be helpful for effective use of metformin in diabetes treatment. In this review, we present microparticulate gastroretentive delivery systems developed to enhance the oral bioavailability of metformin.
Highlights
The incidence of type II diabetes has dramatically increased throughout the world in recent years
An interest increased towards novel drug delivery systems (DDSs) that can remain in the stomach for an extended and predictable period of time
Recent studies reported that incomplete absorption of metformin can be improved using convenient microparticulate gastroretentive DDSs (MGDDSs) [4]
Summary
The incidence of type II diabetes has dramatically increased throughout the world in recent years. Metformin is an oral antihyperglycemic agent widely used for lowering blood glucose concentrations in patients with type II diabetes [1,2]. An interest increased towards novel drug delivery systems (DDSs) that can remain in the stomach for an extended and predictable period of time. Recent studies reported that incomplete absorption of metformin can be improved using convenient microparticulate gastroretentive DDSs (MGDDSs) [4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
